Table 3.
Second-line treatment regimens, overall (2004–2018), and by first-line treatment initiation period (pre- and post-2010).
| Perioda | 2004–2018 | Pre-2010 | Post-2010 |
|---|---|---|---|
| Regimen groups, N (%)b | |||
| Patients, N | 1759 | 775 | 984 |
| Bor-based | 548 (31.2) | 349 (45.0) | 199 (20.2) |
| IMiD-based | 639 (36.3) | 229 (29.5) | 410 (41.7) |
| Chemo | 243 (13.8) | 124 (16.0) | 119 (12.1) |
| Rituximab-based | 57 (3.2) | 11 (1.4) | 46 (4.7) |
| Dara-based | 54 (3.1) | – | 54 (5.5) |
| Steroids | 9 (0.5) | 8 (1.0) | 1 (0.1) |
| ASCT | 128 (7.3) | 32 (4.1) | 96 (9.8) |
| Clinical trial | 38 (2.2) | 12 (1.5) | 26 (2.6) |
| Other regimen groups | 43 (2.4) | 10 (1.3) | 33 (3.4) |
| Individual regimens, N (%) | |||
| Patients, N | 1759 | 775 | 984 |
| ASCT | 128 (7.3) | 32 (4.1) | 96 (9.8) |
| VCD | 156 (8.9) | 95 (12.3) | 61 (6.2) |
| MDex | 138 (7.8) | 71 (9.2) | 67 (6.8) |
| VMD | 31 (1.8) | 11 (1.4) | 20 (2) |
| RD | 382 (21.7) | 53 (6.8) | 329 (33.4) |
| VD | 270 (15.3) | 203 (26.2) | 67 (6.8) |
| CTD | 119 (6.8) | 80 (10.3) | 39 (4) |
| Clinical trial | 38 (2.2) | 12 (1.5) | 26 (2.6) |
| Other individual regimens | 497 (28.3) | 218 (28.1) | 279 (28.4) |
ASCT autologous stem cell transplantation, Bor bortezomib, Chemo chemotherapy, CTD cyclophosphamide, thalidomide, and dexamethasone, Dara daratumumab, IMiD immunomodulatory drugs, MDex melphalan and dexamethasone, N number of patients, RD lenalidomide and dexamethasone, VCD bortezomib, cyclophosphamide, and dexamethasone, VD bortezomib and dexamethasone, VMD bortezomib, melphalan, and dexamethasone.
aPre- and post-2010 indicate the periods of 2004–2010 and 2011–2018, respectively.
bPercentages are calculated using the total number of patients in each column as the denominator.